Epigenetic reprograming of immune cells through selective inhibition of HDAC6 reduces suppressive phenotypes and augments anti-tumor properties of T-cells

被引：1
|
作者：
Sodre, Andressa L.
Woods, David M.
Sarnaik, Amod
Betts, Brian C.
Quayle, Steven
Jones, Simon
Weber, Jeffrey
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-638
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
638
引用
收藏
页数：2
相关论文
共 50 条
  • [1] HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics
    Laino, Andressa S.
    Betts, B. C.
    Veerapathran, A.
    Dolgalev, I.
    Sarnaik, A.
    Quayle, S. N.
    Jones, S. S.
    Weber, J. S.
    Woods, David M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [2] Epigenetic reprogramming by selective HDAC inhibition augments anti-tumor immunity and cancer immunotherapy
    Cheng, Alfred S.
    CANCER SCIENCE, 2023, 114 : 195 - 195
  • [3] Selective Inhibition of HDAC6 augments T-cell central memory and enhances anti-tumor functions: Implications in TIL therapy
    Laino, Andressa Sodre
    Woods, David M.
    Sarnaik, Amod
    Weber, Jeffrey
    Sotomayor, Eduardo M.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [4] HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells
    Oba, Takaaki
    Ono, Mayu
    Matoba, Hisanori
    Uehara, Takeshi
    Hasegawa, Yoshie
    Ito, Ken-ichi
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (01) : 37 - 51
  • [5] HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells
    Takaaki Oba
    Mayu Ono
    Hisanori Matoba
    Takeshi Uehara
    Yoshie Hasegawa
    Ken-ichi Ito
    Breast Cancer Research and Treatment, 2021, 186 : 37 - 51
  • [6] Selective HDAC6 inhibition by SP-2-225 enhances the innate anti-tumor immune response after radiation exposure
    Grindrod, Scott
    Noonepalle, Satish
    Li, Xingtang
    Quiceno, David
    Jung, Mira
    Dritschilo, Anatoly
    Villagra, Alejandro
    CANCER RESEARCH, 2024, 84 (01)
  • [7] Stimulating anti-tumor immune response: the problem of regulatory T-cells
    James, C. David
    NEURO-ONCOLOGY, 2011, 13 (12) : 1261 - 1261
  • [8] HDAC6 INHIBITION SENSITIZES TUMOR CELLS TO ANTI-CD20 IMMUNOTHERAPY IN VIVO
    Bobrowicz, M.
    Dwojak, M.
    Stachura, J.
    Angelika, M.
    Beata, P.
    Marta, S.
    Miazek, N.
    Zapala, P.
    Golab, J.
    Winiarska, M.
    HAEMATOLOGICA, 2017, 102 : 568 - 568
  • [9] Selective inhibition of HDAC6 by N-acylhydrazone derivative reduces the proliferation and induces senescence in carcinoma hepatocellular cells
    Ferreira-Silva, Guilherme Alvaro
    Rodrigues, Daniel Alencar
    Pressete, Carolina Girotto
    Caixeta, Ester Siqueira
    Gamero, Angel Mauricio Castro
    Miyazawa, Marta
    Hanemann, Joao Adolfo Costa
    Fraga, Carlos Alberto Manssour
    Aissa, Alexandre Ferro
    Ionta, Marisa
    TOXICOLOGY IN VITRO, 2024, 99
  • [10] HDAC6 and DNMT inhibition affect immunogenicity of ovarian cancer cells: A rationale for combining epigenetic and immune therapy in ovarian cancer
    Srivastava, Aneil P.
    Moufarrij, Sara M.
    Hadley, Melissa
    Chisholm, Sarah
    Lopez-Acevedo, Micael
    Villagra, Alejandro
    Chiappinelli, Katherine B.
    CANCER RESEARCH, 2018, 78 (13)
12345